Search Result

Isoforms Recommended:	CA I CA

Results for "

hCA+I

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Antibiotic (1) Apoptosis (2) Bacterial (3) Carbonic Anhydrase (83) CDK (1) Cholinesterase (ChE) (13) DNA/RNA Synthesis (1) Endogenous Metabolite (3) Fungal (1) Glycosidase (1) HSV (1) JNK (1) mTOR (3) NKCC (3) NOD-like Receptor (NLR) (1) p38 MAPK (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Small Interfering RNA (siRNA) (1) VEGFR (3)
By Research Areas:	Cancer (47) Cardiovascular Disease (3) Endocrinology (1) Infection (9) Inflammation/Immunology (7) Metabolic Disease (8) Neurological Disease (24)
Click Chemistry:	Azide (1)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-118467

Benzolamide 2 Publications Verification CL11366	Carbonic Anhydrase	Neurological Disease Cancer
Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with K_is of 15 nM, 9 nM, 94 nM and 78 nM for *hCA I, hCA* II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a K_i of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .

HY-69085

4-Bromo-1H-indazole	Carbonic Anhydrase	Others
4-Bromo-1H-indazole is a carbonic anhydrase inhibitor, with an IC₅₀ of 0.403 mM and a K_i of 0.383 mM against hCA-I, as well as an IC₅₀ of 0.700 mM and a K_i of 0.935 mM against hCA-II. 4-Bromo-1H-indazole reduces the catalytic activity of human I and II isoforms of carbonic anhydrase .

HY-163109

Carbonic anhydrase inhibitor 16	Carbonic Anhydrase	Infection
Carbonic anhydrase inhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonic anhydrase *hCA I* and hCA II (K_i: 28.5 nM, 2.2 nM) .

HY-147986

hCA I-IN-2	Carbonic Anhydrase	Cancer
hCA I-IN-2 (Compound 6d) is a selective human carbonic anhydrase I (hCA I) inhibitor with K_i values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .

HY-147985

hCA I-IN-1	Carbonic Anhydrase	Cancer
hCA I-IN-1 (Compound 6q) is a human carbonic anhydrase I (hCA I) inhibitor with K_i values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .

HY-W008343

1,3-Dimethyluracil	Endogenous Metabolite	Metabolic Disease
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against *hCA I* and hCA II (human carbonic anhydrase) with K_i of 316.2 μM and 166.4 μM, respectively .

HY-W012168

4-Chloro-3-sulfamoylbenzoic acid	Carbonic Anhydrase	Metabolic Disease
4-Chloro-3-sulfamoylbenzoic acid is a weak inhibitor of human carbonic anhydrase isoforms *hCA I, hCA* II, hCA IV, and hCA IX, and a synthesis intermediate for carbonic anhydrase inhibitors. 4-Chloro-3-sulfamoylbenzoic acid is the major metabolite of tripamide detected in tissues, urine, and feces of rats and rabbits following Tripamide (HY-106570) administration. 4-Chloro-3-sulfamoylbenzoic acid can be used for the study of carbonic anhydrase inhibition and species differences in drug metabolism .

HY-W044762

5,6-Dihydro-2H-pyran-2-one	Carbonic Anhydrase	Cancer
5,6-Dihydro-2H-pyran-2-one (Compound 1) is a prodrug-type carbonic anhydrase inhibitor. 5,6-Dihydro-2H-pyran-2-one can specifically inhibit the tumor-associated subtype hCA IX and the cytoplasmic subtype *hCA I* with K_i values of 1.35 and 8.03 μM. 5,6-Dihydro-2H-pyran-2-one can be used for the research on hypoxia-related cancer .

HY-175847

hCA-I/hCA-II-IN-2	Carbonic Anhydrase	Cancer
hCA-I/ HCA-II-IN-2 (compound 5 k) is an effective inhibitor of human carbonic anhydrase I (hCA-I) and II (hCA-II). The IC₅₀ for hCA I and hCA II are 89.25 and 54.50 nM respectively .

HY-B1471

Fluorometholone acetate 1 Publications Verification	Carbonic Anhydrase	Inflammation/Immunology
Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC₅₀s of 2.18 μM and 17.5 μM for *hCA-I* and *hCA-II*, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .

HY-146206

HCAIX-IN-1	Carbonic Anhydrase	Cancer
HCAIX-IN-1 (compound 21e) is a potent and selective HCAIX inhibitor with K_Is of 694.9, 126.6, 3.3, 9.8 nM for hCA I, hCA II, hCA IX, hCA XII, respectively .

HY-174835

hCA-I/hCA-II-IN-1	Carbonic Anhydrase	Cardiovascular Disease
hCA-I/hCA-II-IN-1 (Compound P4) is a potent dual human carbonic anhydrase I (hCA-I) and human carbonic anhydrase II (hCA-II) inhibitor with K_i values of 0.22 μM and 0.33 μM, respectively. hCA-I/hCA-II-IN-1 can be used in research on diseases related to CA enzymes such as glaucoma, hypertension, and ulcers .

HY-147925

hCAI/II-IN-4	Carbonic Anhydrase	Others
hCAI/II-IN-4 (compound 6d) is a potent dual *hCA I/II* inhibitor with K_i values of 16.95, 15.22 and 27.04 nM for hCA I, hCA II and hCA Ⅸ, respectively. hCAI/II-IN-4 has anti-hypoxia activities and low toxicity. hCAI/II-IN-4 can be used for acute mountain sickness (AMS) research .

HY-147922

hCAI/II-IN-2	Carbonic Anhydrase	Inflammation/Immunology
hCAI/II-IN-2 (compound 2b) is a potent dual *hCA I/II* inhibitor with K_i values of 40.97, 15.15 and 61.88 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-2 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .

HY-147923

hCAI/II-IN-3	Carbonic Anhydrase	Inflammation/Immunology
hCAI/II-IN-3 (compound 5b) is a potent dual *hCA I/II* inhibitor with K_i values of 51.25, 13.15 and 42.18 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-3 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .

HY-157321

hCAI/II-IN-7	Carbonic Anhydrase	Neurological Disease
hCAI/II-IN-7 (compound 1F) is a potent carbonic anhydrase (CA) inhibitor with K_i values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively .

HY-146385

hCAI/II-IN-1	Carbonic Anhydrase	Cancer
hCAI/II-IN-1 (Compound 3h) is a human carbonic anhydrase I and II (hCA I/II) inhibitor with IC₅₀ values of 0.047 µM and 0.024 µM against hCA I and hCA II, respectively .

HY-161507

hCAI/II-IN-8	Carbonic Anhydrase Cholinesterase (ChE)	Metabolic Disease
hCAI/II-IN-8 (Compound 8) is a hydrazide derivative based on 4-hydroxybenzaldehyde. hCAI/II-IN-8 primarily targets human carbonic anhydrase isomerase I (hCA I) and II (hCA II) for inhibition (IC₅₀ = 21.35 ± 0.39 nM (hCA I); 7.12 ± 0.12 nM (hCA II)). hCAI/II-IN-8 inhibits AChE and BChE as well(IC₅₀ = 46.27 ±0.75 nM (AChE); 43.38 ± 0.83 nM (BChE)). . .

HY-176055

hCAI/II-IN-11	Carbonic Anhydrase	Infection
hCAI/II-IN-11 (compound 2c) is a Carbonic Anhydrase Inhibitor with IC₅₀ values of 12.56 μM and 13.02 μM for hCA I and hCA II, respectively. hCAI/II-IN-11 shows antioxidant and antimicrobial effects .

HY-172103

hCAI/II-IN-10	Carbonic Anhydrase	Others
hCAI/II-IN-10 (Compound 5d) is a human carbonic anhydrase I and II (hCA I and hCA II) inhibitor with IC₅₀ values are 4.32 and 3.89 nM respectively .

HY-148135

hCAI/II-IN-6	Carbonic Anhydrase	Neurological Disease
hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with K_i values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .

HY-147955

hCAI/II-IN-5	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease Metabolic Disease
hCAI/II-IN-5 (compound MZ8) is a potent *hCA I* and hCA II (human carbonic anhydrase isoenzymes I and II) inhibitor, with IC₅₀ values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC₅₀ values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy .

HY-W031519

Chloraminophenamide	Carbonic Anhydrase	Cardiovascular Disease
Chloraminophenamide (Compound 14) is a carbonic anhydrase inhibitor, with *K_is of 75, 160 and 8400 nM for hCA* II, bCA IV and *hCA I, respectively. Chloraminophenamide has the potential for antiglaucoma research .*

HY-144376

Carbonic anhydrase inhibitor 4	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 4 is carbonic anhydrase photoprobe/inhibitor. Carbonic anhydrase inhibitor 4 is against human carbonic anhydrases (hCA I-XIV) with K_i values of 640-1166 nM .

HY-175972

CAI/II-IN-12	Carbonic Anhydrase	Neurological Disease Cancer
CAI/II-IN-12 is a potent and hCAI (IC₅₀ = 7.12 μM, K_i = 9.26 μM) and hCAII (IC₅₀ = 10.62 μM, K_i = 11.72 μM) dual inhibitor. CAI/II-IN-12 has a strong affinity for the active sites of CYP17A1, hCAI, and hCAII enzymes. Compound CAI/II-IN-12 exhibits rapid conformational stabilization, particularly in the CYP17A1 complex. CAI/II-IN-12 can be used for the study of prostate cancer therapy and glaucoma .

HY-178922

CAI/II-IN-13	Carbonic Anhydrase	Cancer
CAI/II-IN-13 (Compound 5f) is a CAI/II inhibitor, with IC₅₀ values of 309.16 nM for *hCA I* and 267.27 nM for hCA II. CAI/II-IN-13 exhibits potent and selective antiproliferative activity against A549 lung cancer cells (IC₅₀ = 0.58 μM). CAI/II-IN-13 can be used for the study of lung cancer .

HY-150570

Carbonic anhydrase inhibitor 14	Carbonic Anhydrase CDK	Cancer
Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with K_i values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC₅₀ of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity .

HY-101136

Dealanylascamycin AT-265	Antibiotic Carbonic Anhydrase Bacterial	Infection
Dealanylascamycin (AT-265) (Compound 2) is a nucleoside antibiotic. AT 265 is a carbonic anhydrase (CA) inhibitor, with K_i values of 167, 65.2, 234, and 143 nM for *hCA I, hCA* II, hCA IV, and hCA IX respectively. Dealanylascamycin is the active form of Ascamycin (HY-121071). Dealanylascamycin exhibits broad-spectrum antibacterial activity and is effective against pathogenic bacteria such as Xanthomonas citri (MIC = 0.4 μg/mL). Dealanylascamycin has high cytotoxicity .

HY-170560

*AChE/hCA I-IN-1*	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease
AChE/hCA I-IN-1 (Compound L3) is the inhibitor for acetylcholinesterase (AChE) and carbonic anhydrase (CA), that inhibits AChE, *hCA I* and hCA II with IC₅₀ of 302, 265 and 283 nM, respectively .

HY-178362

CAII/VII-IN-1	Carbonic Anhydrase NKCC mTOR	Neurological Disease
CAII/VII-IN-1 is an orally active hCA II (K_I = 12.3 nM), and hCA VII (K_I = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy .

HY-169962

hCA I-IN-4	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease Cancer
hCA I-IN-4 (Compound 14) is the inhibitor for carbonic anhydrase and cholinesterase, that inhibits *hCA I, hCA* II, AChE, and BChE with K_i of 29.94 nM, 17.72 nM, 21.21 nM, and 7.65 nMrespectively. hCA I-IN-4 exhibits cytotoxicity in BT-549 with IC₅₀ of 16.59 μM .

HY-158372

hCA I-IN-3	Carbonic Anhydrase	Cancer
hCA I-IN-3 (compound 24), an aryl ether derivative, is a potent carbonic anhydrase inhibitor. hCA I-IN-3 can inhibit carbonic anhydrase *hCA I* and hCA II isoenzymes, with IC₅₀ values of 4.77 and 9.66 nM, respectively. hCA I-IN-3 can be used for cancer research .

HY-174252

HSV-1/HSV-2-IN-3	DNA/RNA Synthesis HSV	Infection
HSV-1/HSV-2-IN-3 inhibits the herpes-simplex-virus (HSV) helicase-primase complex, blocking the coordinated DNA-unwinding and primer-synthesis steps required for viral genome replication. HSV-1/HSV-2-IN-3 exhibits an EC₅₀ of 7.0 nM against HSV-2 in a gD-immunofluorescence cell assay containing 2 % FBS and 57.5 nM when 10 % human serum is present. HSV-1/HSV-2-IN-3 achieves an EC₅₀ of 1.1 nM in a qPCR replication assay. HSV-1/HSV-2-IN-3 shows strong selectivity over human carbonic-anhydrase off-targets (IC₅₀ ≈ 2.9 µM for hCA II and > 35 µM for hCA I). HSV-1/HSV-2-IN-3 can be studied in anti-HSV research .

HY-W306065

hCAI/II/XII-IN-1	Carbonic Anhydrase	Cancer
hCAI/II/XII-IN-1 (compound 7) is a human carbonic anhydrase *hCAI/II/XII* inhibitor, with K_i values of 78.5, 9.1, 605, 7.7 and 3.7 nM .

HY-B1471R

Fluorometholone acetate (Standard)	Reference Standards Carbonic Anhydrase	Inflammation/Immunology
Fluorometholone acetate (Standard) is the analytical standard of Fluorometholone acetate. This product is intended for research and analytical applications. Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC₅₀s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .

HY-149012

*AChE/hCA I/II-IN-1*	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease Endocrinology
AChE/hCA I/II-IN-1 (Compound 6) is a potent inhibitor of *AChE/Hca* with IC₅₀ values of 22.21, 60.79 and 66.64 nM for AChE, Hca Ⅰ and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used for the rsearch for glaucoma, Alzheimer's disease, diabetes .

HY-157135

hCAIX-IN-19	Carbonic Anhydrase	Cancer
hCAIX-IN-19 is a sulfonamides inhibitor against hCA IX with an inhibition constant (K_I) of 6.2 nM and show good selectivity over hCA I (hCA I/ hCA IX = 117) .

HY-RS03446

CYP24A1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP24A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP24A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP24A1 Human Pre-designed siRNA Set A CYP24A1 Human Pre-designed siRNA Set A

HY-129986

hCAI/II-IN-9	Endogenous Metabolite	Others
hCAI/II-IN-9 is a carbonic anhydrase inhibitor with inhibitory activity against human carbonic anhydrase isoforms I, II, IX, and XII. The inhibition constants (Ki) of hCAI/II-IN-9 for hCA I are in the range of 7.9-894 nM, for hCA II are in the range of 7.5-1645 nM, for hCA IX are in the range of 5.0-240 nM, and for hCA XII are in the range of 0.47-2.83 nM. hCAI/II-IN-9 may have potential applications in inhibiting a variety of pathologies involving these carbonic anhydrase isoforms .

HY-172607

Carbonic anhydrase inhibitor 30	Carbonic Anhydrase	Infection
Carbonic anhydrase inhibitor 30 (compound 17) is an inhibitor of carbonic anhydrase with K_i values of 2.13 μM and 0.161 nM for hCA I and hCA II, respectively ^{[1] ^.}

HY-163660

Carbonic anhydrase inhibitor 23	Carbonic Anhydrase	Infection
Carbonic anhydrase inhibitor 23 (compound 40) is a potent inhibitor of carbonic anhydrase (CA), with the K_i of 617.2 nM and 434.1 nM for hCA I (α) and hCA II (α), respectively .

HY-161142

Carbonic anhydrase/AChE-IN-1	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease
Carbonic anhydrase/AChE-IN-1 (compound 16) is a carbonic anhydrase and AChE inhibitor with K_is of 24.42 nM, 19.95 nM, and 5.07 nM for hCA I, hCA II, and AChE, respectively .

HY-144268

hCAII-IN-7	Carbonic Anhydrase	Cancer
hCAII-IN-7 (Compound R-13) is a potent human carbonic anhydrase *(hCA)* inhibitor with K_is of 60.7, 320.7, 2298, and 35.2 nM for hCA I, II, IV and IX, respectively .

HY-162063

hCAIX/XII-IN-9	Carbonic Anhydrase	Inflammation/Immunology Cancer
hCAIX/XII-IN-9 (compound 8) is a potent carbonic anhydrase (CA) inhibitor with K_i values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively .

HY-168603

AChE/CA I-IN-1	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease
AChE/CA I-IN-1 (Compound 2g) is the inhibitor for AChE and *hCA I* with K_i of 1.85 and 0.53 µM. AChE/CA I-IN-1 exhibits potential application in researches about Alzheimer's disease, glaucoma, and epilepsy .

HY-144641

Carbonic anhydrase inhibitor 7	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 7 (compound 5b) is a potent inhibitor of human carbonic anhydrase (hCA), with K_is of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and *hCA I*, respectively .

HY-144640

Carbonic anhydrase inhibitor 6	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 6 (compound 9b) is a potent inhibitor of human carbonic anhydrase (hCA), with K_is of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and *hCA I*, respectively .

HY-146355

hCAII-IN-2	Carbonic Anhydrase	Cancer
hCAII-IN-2 (Compound 11f) is a cytosolic human carbonic anhydrase (hCA) inhibitor with K_i values of 261.4, 3.8, 19.6 and 45.2 nM against *hCA I, hCA* II, hCA IX and hCA XII, respectively .

HY-132156

Carbonic anhydrase inhibitor 22	Carbonic Anhydrase	Neurological Disease
Carbonic anhydrase inhibitor 22 (Compd 2g), a sulfonamide carbonic anhydrase inhibitor, with K_i values of 762 nM (hCA I), 20.3 nM (hCA II), 8.3 nM (hCA VII), 17.9 nM (hCA IX) and 10.5 nM (hCA XII), repectively .

HY-147829

hCAXII-IN-2	Carbonic Anhydrase	Cancer
hCAXII-IN-2 (compound 5i) is a potent *human carbonic anhydrase XII (hCA* XII)** and hCA IX inhibitor with K_i values of 84.2 nM and 268.5 nM, respectively. hCAXII-IN-2 shows less active against hCA I and hCA II .

Cat. No.	Product Name		Classification

HY-159128

hCAIX-IN-21		Azide
hCAIX-IN-21 (compound 16c) is a potent hCAIX inhibitor with K_I values of 5.2, 3.5, 12.6, 13600 nM for hCAIX, hCA II, hCA XII, hCA I, respectively. hCAIX-IN-21 inhibits cathepsin B enzyme activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks